scholarly journals Age moderates the associations between TRAbs, free T3 and outcomes of Graves’ disease patients with radioactive iodine treatment

2020 ◽  
Author(s):  
Lusi Lu ◽  
Chenlu Gao ◽  
Nan Zhang
2019 ◽  
Vol 43 (3) ◽  
pp. 381-383 ◽  
Author(s):  
S. Rosetti ◽  
M. L. Tanda ◽  
G. Veronesi ◽  
E. Masiello ◽  
P. Premoli ◽  
...  

2021 ◽  
Vol 111 (2) ◽  
pp. 176
Author(s):  
F Docrat ◽  
T Mokoena ◽  
V O L Karusseit ◽  
A O Ankrah

2013 ◽  
Vol 4 (4) ◽  
pp. 1-4 ◽  
Author(s):  
Catherine Hyams ◽  
Pavan Joshi ◽  
Paul Foster ◽  
Jonathan Katz

2017 ◽  
Vol 25 (4) ◽  
pp. 314-318 ◽  
Author(s):  
Siba El Hussein ◽  
Yumna Omarzai

Unlike the well-documented relation between radiation to the neck and development of papillary thyroid carcinoma, a causal association between radioactive iodine treatment for Graves’ disease and development of thyroid malignancy is less defined. However, patients with a background of thyroid dysfunction presenting with clinically palpable thyroid nodules are followed more closely than the average population, and fine needle aspiration is recommended in such circumstances. Cytological examination of aspirates, and histologic examination of tissue provided from patients with a known history of Graves’ disease, managed by radioactive iodine therapy can create a diagnostic dilemma, as the distinction between radiation effect and a malignant primary thyroid neoplasm can be very challenging. Thus, pathologists should be aware of the existence of these changes in the setting of radiation therapy for Graves’ disease. Providing pathologists with appropriate clinical history of Graves’ disease treated with radioactive iodine is of paramount importance in order to prevent an overdiagnosis of malignancy.


Author(s):  
Ferhat Arık ◽  
Ferhat Gökay ◽  
Bade Erturk Arık

Objective: Hyperthyroidism is an increase in hormone production in the thyroid gland and the exposure of tissues to the hormones of the thyroid glands in the circulation. The most common causes encountered are Graves’ Disease, Toxic Multinodular Goiter and Toxic Adenoma. The purpose of radioactive iodine treatment is to make patients become euthyroid or hypothyroid. Despite adequate treatment, hyperthyroidism persists or reccurs in some patients. The aim of our study is to investigate the factors affecting the efficacy of radioactive iodine treatment in hyperthyroidism. Methods: In this retrospective study, relevant clinical and laboratory data were recorded in database of Kayseri Training and Research Hospital, Endocrinology and Metabolism Diseases Outpatient Unit between 2013-2016. Results: A total of 79 cases including 17 (21%) male, and 62 (79%) female patients were enrolled in the study. There were 33 (42%) Graves’ disease 9 (11%) Toxic Multinodular Goitre and 37 (47%) Toxic Adenoma patients when grouped according to diagnoses. Mean age was 56.5 ± 16,80. Development of hypothyroidism or euthyroidism were accepted as efficient treatment, hyperthyroidism or recurrence were considered as treatment failure. In 71 (89%) patients, treatment efficiently resulted in hypothyroidism or euthyroidism, whereas in 8 (11%) patients, the treatment failed due to recurrence or persistent disease. Treatment was 100 % effective in Toxic Multinodular Goitre and Toxic Adenoma groups, while it was effective in 75.7 of patients with Graves’ Disease. Patients who did not use antithyroid drugs recovered faster than patients who did. Conclusion: Radioactive iodine therapy is an efficient treatment in patients with hyperthyroidism. It was determined that 1 mm increase in nodule size decreased the treatment efficacy by 1.07 times (p<0,05). However, there are many factors that affect the efficacy of this treatment. To elucidate these factors and improve clinical practice, prospective long-term studies providing more reliable data with larger samples needed.


Sign in / Sign up

Export Citation Format

Share Document